Increased Risk of End-Stage Renal Disease (ESRD) Requiring Chronic Dialysis is Associated With Use of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Abstract

Supplemental Digital Content is available in the text

Relative risk of end-stage renal disease requiring dialysis in treated ankylosing spondylitis patients compared with individuals without ankylosing spondylitis: A nationwide, population-based, matched-cohort study

“…This finding might be explained by reverse causality (i.e., impaired baseline renal function leading to more frequent follow-up). Consistent with a study by Chang et al PLOS ONE [25], we found that use of selective COX-2 inhibitors was associated with an increased risk of ESRD. However, use of preferential COX-2i tended to be associated with a lower risk of ESRD requiring dialysis (HR, 0.37; 95% CI, 0.12-1.09; p-value = 0.071).…”

“…Given that use of NSAIDs is one of the most critical risk factors for the development of ESRD [25], we re-selected 6,621 AS patients and 6,621 non-AS subjects by further matching (1:1) for cDDDs of three groups of NSAIDs to estimate the risk of developing ESRD requiring dialysis associated with AS. Table 3 shows a comparison of the demographic and clinical data from both groups.…”

Developing Treatments for Chronic Kidney Disease in the 21st Century

“…It remains controversial as to whether a drug that reduces proteinuria via any mechanism would provide renal benefit, 67,68 or if a reduction in proteinuria also must be accompanied by acute eGFR and blood pressure reduction to achieve renal benefit. For instance, nonsteroidal anti-inflammatory drugs can acutely reduce proteinuria and glomerular hyperfiltration, 69 but increase blood pressure and are associated with increased cardiovascular mortality and renal events, 70–73 making their utility in treating CKD questionable. Two recent phase 2 diabetic nephropathy trials of a NOX1/4 inhibitor, GKT137831, and a phosphodiesterase inhibitor, CTP-499, failed to observe any detectable effect on any of these parameters (Table 1).…”

Improvement of the efficacy and safety of the treatment of patients with low back pain

“…Нефротоксический эффект в большей степени присущ неселективным ингибиторам ЦОГ, и, как правило, развивается на протяжении 1-го месяца терапии [20]. В случае наличия других факторов риска развития хронической болезни почек даже кратковременный прием НПВС может привести к почечной недостаточности, требующей проведения гемодиализа [21]. Имеются данные о том, что фактором риска нефротоксического эффекта НПВС является сопутствующая артериальная гипертензия [22].…”